BioSpace News Archive

Alkermes plc (Nasdaq: ALKS) announced today that its Senior Vice President of Corporate Planning, Blair Jackson, will participate in a fireside chat at the UBS Global Healthcare Conference on Monday, May 20, 2019 at 8:00 a.m. ET (1:00 p.m. BST) from New York.

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care, gastroenterology, and oncology supportive care today announced first quarter 2019 financial results with net revenues of $11.9 million, up 38% over the prior year quarter

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today reported financial results for the first quarter ended March 31, 2019 and provided an update on recent operational highlights.

Stealth BioTherapeutics (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at the UBS Global Healthcare Conference in New York on Tuesday, May 21st 2019, at 2:30pm ET.

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), will host an Analyst and Investor Conference in New York City on Tuesday, June 18, 2019. Management will provide an update on the business, with presentations starting at 9:00 a.m. ET and concluding at approximately 1:00 p.m. ET.

Exelixis, Inc. (Nasdaq: EXEL) today announced that the company will be presenting at the following two investor conferences on Tuesday, May 21, 2019, in New York:

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended March 31, 2019.

Andrew Pecora, MD, FACP, CPE, has been named chief executive officer (CEO) of Outcomes Matter Innovations, (OMI) LLC, it was announced today.

The 3M Board of Directors declared a dividend on the company’s common stock of $1.44 per share for the second quarter of 2019.

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of targeted immunotherapies using fully human monoclonal antibodies (mAbs) to treat life-threatening bacterial infections, today reported financial and corporate results for the first quarter ended March 31, 2019.